Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
Autolus Therapeutics (Nasdaq: AUTL), a biopharmaceutical company focused on next-generation programmed T cell therapies, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:30 AM EDT/1:30 PM BST featuring management's discussion of financial results and a business update. Participants must pre-register to receive dial-in details and a personal PIN for the call. A simultaneous audio webcast and replay will be available on the company's website events section.
Autolus Therapeutics (Nasdaq: AUTL), un'azienda biofarmaceutica specializzata in terapie di prossima generazione con cellule T programmate, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 12 agosto 2025, prima dell'apertura dei mercati statunitensi.
L'azienda terrà una conference call e una webcast alle 8:30 AM EDT/1:30 PM BST, durante le quali la direzione discuterà i risultati finanziari e fornirà un aggiornamento sull'attività. I partecipanti devono registrarsi anticipatamente per ricevere i dettagli di accesso e un PIN personale per la chiamata. Una trasmissione audio simultanea e una registrazione saranno disponibili nella sezione eventi del sito web aziendale.
Autolus Therapeutics (Nasdaq: AUTL), una compañía biofarmacéutica centrada en terapias de células T programadas de próxima generación, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 12 de agosto de 2025, antes de la apertura de los mercados en EE. UU.
La empresa realizará una llamada conferencia y una transmisión web a las 8:30 AM EDT/1:30 PM BST, donde la dirección discutirá los resultados financieros y proporcionará una actualización comercial. Los participantes deben registrarse previamente para recibir los detalles de acceso y un PIN personal para la llamada. Habrá una transmisión de audio simultánea y una repetición disponible en la sección de eventos del sitio web de la compañía.
Autolus Therapeutics (나스닥: AUTL)는 차세대 프로그래밍된 T 세포 치료제에 집중하는 생명공학 회사로, 2025년 8월 12일 미국 시장 개장 전에 2025년 2분기 재무 실적 발표를 예정하고 있습니다.
회사는 동부 표준시 오전 8:30 / 영국 서머타임 오후 1:30에 경영진이 재무 결과 및 사업 현황을 논의하는 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다. 참가자는 사전에 등록하여 전화 접속 정보와 개인 PIN을 받아야 합니다. 회사 웹사이트의 이벤트 섹션에서 동시 오디오 웹캐스트와 재방송도 제공됩니다.
Autolus Therapeutics (Nasdaq : AUTL), une entreprise biopharmaceutique spécialisée dans les thérapies cellulaires T programmées de nouvelle génération, a prévu d’annoncer ses résultats financiers du deuxième trimestre 2025 le 12 août 2025, avant l’ouverture des marchés américains.
La société organisera une conférence téléphonique et une webdiffusion à 8h30 EDT / 13h30 BST, au cours desquelles la direction présentera les résultats financiers et fera un point sur les activités. Les participants doivent s’inscrire à l’avance pour recevoir les informations d’accès et un code PIN personnel pour l’appel. Une webdiffusion audio simultanée ainsi qu’un replay seront disponibles dans la section événements du site internet de la société.
Autolus Therapeutics (Nasdaq: AUTL), ein biopharmazeutisches Unternehmen, das sich auf die nächste Generation programmierter T-Zell-Therapien spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 12. August 2025 geplant, und zwar vor Öffnung der US-Märkte.
Das Unternehmen wird um 8:30 Uhr EDT / 13:30 Uhr BST eine Telefonkonferenz und einen Webcast veranstalten, bei denen das Management die Finanzergebnisse und ein Geschäftsupdate präsentiert. Teilnehmer müssen sich vorab registrieren, um Einwahldaten und eine persönliche PIN für den Anruf zu erhalten. Ein gleichzeitiger Audiowebcast und eine Aufzeichnung werden im Veranstaltungsbereich der Unternehmenswebsite verfügbar sein.
- None.
- None.
LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 12, 2025.
Management will host a conference call and webcast at 8:30am EDT/13:30pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
FAQ
When will Autolus Therapeutics (AUTL) release Q2 2025 earnings?
What time is the Autolus Therapeutics (AUTL) Q2 2025 earnings call?
How can I access the Autolus Therapeutics Q2 2025 earnings call?
What does Autolus Therapeutics (AUTL) do?
